Curevac Story

CVAC -- USA Stock

USD 101.07 0.02 0.0198%

Macroaxis Story

Curevac NV is scheduled to announce its earnings today. The stock is undergoing an active upward rally. As many millenniums are trying to avoid healthcare space, it makes sense to go over Curevac NV a little further and try to understand its current market patterns. Here we also measure the ability of Curevac NV to meet its long-term debt obligations, such as interest payments on debt, the final principal payment on the debt, and any other fixed obligations like lease payments.

Published over a month ago

View all stories for Curevac NV | View All Stories

How much will Curevac NV owe in December?

The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Curevac suggests not a very effective usage of assets in November.

Curevac NV financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Curevac NV, including all of Curevac NV's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Curevac NV assets, the company is considered highly leveraged. Understanding the composition and structure of overall Curevac NV debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.

Understanding Curevac Total Debt

Curevac NV liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Curevac NV has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Curevac NV balance sheet include debt obligations and money owed to different Curevac NV vendors, workers, and loan providers. Below is the chart of Curevac main long-term debt accounts currently reported on its balance sheet.

You can use Curevac NV financial leverage analysis tool to get a better grip on understanding its financial position

How Curevac utilizes its cash?

To perform a cash flow analysis of Curevac NV, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Curevac NV is receiving and how much cash it distributes out in a given period. The Curevac NV cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Curevac NV Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (78.27 Million)

Another angle On Curevac NV

Asset Breakdown

75.1 M

Assets Non Current

57.5 M

Current Assets

	Total Assets	142.93 Million
	Current Assets	57.51 Million
	Assets Non Current	75.14 Million
	Goodwill	5.51 Million
	Tax Assets	119,000

Can Curevac NV build up on the current rise?

Curevac NV current standard deviation builds up over 5.02. Curevac NV shows above-average downside volatility for the selected time horizon. We advise investors to inspect Curevac NV further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Curevac NV future alpha.

Our Final Take On Curevac NV

Whereas some firms within the biotechnology industry are still a little expensive, even after the recent corrections, Curevac NV may offer a potential longer-term growth to investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither acquire nor drop any shares of Curevac NV at this time. The Curevac NV risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Curevac NV.

About Contributor

Achuva Shats is a Member of Macroaxs Editorial Board. Achuva writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Curevac NV. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC